INV4
2月前
AGA Precision Systems Signs Second Long-Term Supply Agreement to Manufacture Aerospace and Defense Components for a Tier 1 Firm
April 9, 2026
AGA Precision Systems LLC (“AGA”), an ITAR-registered and AS9100-certified precision CNC aerospace and defense manufacturing company and subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced the execution of a Long-Term Agreement (“LTA”) with globally recognized Tier 1 aerospace and defense company. The LTA formalizes an ongoing multi-year supplier-customer relationship and governs future purchase orders issued during its term. This marks AGA’s second long-term agreement with an aerospace and defense customer, following the execution of an LTA with Turbo-Jet Products Co., Inc. announced March 31, 2026, and reflects AGA’s continued progress in establishing its position as a qualified supplier within the U.S. defense supply chain.
Under the LTA, AGA will supply precision CNC-manufactured components in support of the customer’s aerospace and defense programs. The arrangement includes defined performance commitments across quality, delivery, and pricing, consistent with the standards required for high-consequence, mission-critical defense applications.
Strategic Significance
AGA believes securing a long-term agreement with a Tier 1 defense company reflects the maturity of AGA’s precision manufacturing capabilities and its customers’ confidence in AGA’s ability to meet stringent technical and regulatory requirements, including ITAR, and AS9100. AGA believes long-term agreements of this nature provide operational visibility, support recurring revenue potential, and reinforce AGA’s position as a reliable, qualified supplier within the broader U.S. aerospace and defense industrial base.
Due to confidentiality obligations and applicable regulatory requirements, including ITAR, AGA is not disclosing the identity of the customer at this time. Should the LTA become material, AGA intends to make additional disclosures in accordance with any applicable reporting obligations; however, no assurance can be given at this time.
About AGA Precision Systems LLC
AGA Precision Systems LLC is a California-based specialized computer numerical control (CNC machine shop focused on high-tolerance milling, turning, mold manufacturing, and the machining of complex metals including titanium, Inconel, stainless steel, and aluminum alloys. The company serves customers across the aerospace, defense, space, and industrial sectors, delivering mission-critical precision components to demanding technical specifications.
AGA is AS9100 certified and ITAR registered, meeting globally recognized quality management standards for aerospace manufacturing and adhering to strict U.S. regulatory requirements governing defense-related work.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Link article
$ELAB 🗞️
iHub News
2月前
PMGC completes full drawdown of $20M equity facility with StreetervilleApril 8, 2026 11:09 AM
IH Market News
PMGC Holdings Inc. (NASDAQ:ELAB) said it has fully utilized the $20 million commitment available under its equity purchase agreement with Streeterville Capital, LLC, according to a company press release.The funding supported a series of acquisitions completed between July 2025 and February 2026. In July 2025, PMGC acquired Pacific Sun Packaging, Inc., a packaging supplier serving more than 300 customers across semiconductor, data center and IT supply chains, as well as AGA Precision Systems LLC, an AS9100-certified precision CNC machining business. The company later acquired Indarg Engineering, Inc. in October 2025 as a bolt-on addition to AGA. In February 2026, PMGC expanded further with the purchase of SVM Machining, Inc., a precision CNC manufacturer supplying industries including medical devices, aerospace, semiconductors and transportation.These acquisitions span precision CNC manufacturing and specialized IT packaging operations serving sectors such as aerospace, defense, medical technology, semiconductors and data centers. The expansion strategy comes as the company maintains a relatively small market capitalization of roughly $6.68 million and continues to navigate financial challenges.PMGC said its near-term strategy focuses on integrating its recently acquired manufacturing and packaging businesses while pursuing organic growth. The company also plans selective acquisitions within aerospace and defense markets, continued development of subsidiary Northstrive Biosciences Inc.’s biopharmaceutical pipeline—including advancing EL-22 toward a Phase 2 IND filing—and evaluating additional financing options.Management indicated it intends to combine internal growth with targeted acquisitions to expand the company’s operational scale. PMGC Holdings operates as a diversified holding company that builds its portfolio through strategic investments and acquisitions across multiple industries.Separately, PMGC recently reported that total assets increased 43% to about $12.87 million in fiscal 2025, up from $8.99 million in 2024. During the year, the company completed three acquisitions—Pacific Sun Packaging, AGA Precision Systems and additional assets from Indarg Engineering—strengthening its position in precision manufacturing and industrial packaging.The company also launched a new subsidiary, NorthStrive Defense Tech LLC, focused on drone technologies and autonomous defense systems. The unit secured an exclusive option agreement to license patent rights for a drone platform capable of operating in both aerial and aquatic environments.In another development, AGA Precision Systems entered into a long-term supply agreement with Turbo-Jet Products Co., Inc. to provide aerospace and defense components.Meanwhile, PMGC subsidiary Northstrive Biosciences updated its licensing agreement with MOA Life Plus Co., Ltd., revising milestones and timelines tied to pre-clinical trial development. The company said these steps reflect ongoing efforts to strengthen its manufacturing, technology and life sciences capabilities.
Original: PMGC completes full drawdown of $20M equity facility with Streeterville
INV4
2月前
PMGC Holdings Inc. [NASDAQ: ELAB] Fully Utilizes All Available in $20M Equity Financing Facility, Strengthens Cash Position and Advances Multi-Sector Acquisition Strategy
April 8, 2026
PMGC Holdings (NASDAQ: ELAB) has fully utilized a $20.0 million equity purchase facility with Streeterville Capital, strengthening cash to fund near-term acquisitions.
PMGC closed four precision manufacturing and specialty packaging acquisitions from July 2025–February 2026 and advances Northstrive Biosciences' EL-22 toward a Phase 2 IND pathway.
Positive
• $20.0M equity facility fully utilized to fund growth
• Four acquisitions completed between July 2025–Feb 2026
• Acquisitions expand exposure to aerospace, defense, semiconductors, medical devices
• Northstrive EL-22 on FDA-supported path toward Phase 2 IND
Negative
• Equity financing utilization may result in shareholder dilution
• Integration of four acquisitions requires operational execution and cost management
04/08/2026 - 07:30 AM
• Facility Fully Utilized
• Company Maintains Strong Cash Position, Fully Funded for Near-Term Acquisition Pipeline
• Portfolio Spans Aerospace, Defense, Semiconductor, Medical Device, and Data Center Supply Chains
NEWPORT BEACH, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“the Company,” “PMGC,” “we,” or “our”), a diversified holding company, today announced that it has utilized all of the $20 million commitment amount under its equity purchase facility (the “Facility”) with Streeterville Capital, LLC.
History of Strategic Capital Allocation
The Company’s acquisitions over 2025 and Q1 2026 span three precision computer numerical control (“CNC”) manufacturing companies that service large and medium size companies in the aerospace, defense, medical and industrial sectors, and a specialty IT packaging company that serves over 300 commercial customers across North America’s semiconductor, data center, and IT supply chains:
• Pacific Sun Packaging, Inc. — Acquired in July 2025; focused on custom-engineered protective packaging for CPUs, memory modules, SSDs, fiber-optic transceivers, and other high-value semiconductor, AI infrastructure, and data center components; serves over 300 commercial customers across North America’s semiconductor, data center, and IT supply chains.
• AGA Precision Systems LLC (“AGA”) — Acquired in July 2025; ITAR-registered, AS9100-certified precision CNC machine shop focused on complex metals, including titanium and Inconel, for aerospace, defense, and industrial customers.
• Indarg Engineering, Inc. — Acquired in October 2025, under AGA; a bolt-on asset acquisition which expands AGA’s machining capacity to support growing demand from aerospace, space, and industrial customers.
• SVM Machining, Inc. — Acquired in February 2026; a precision CNC manufacturing company serving medical device and surgical robotics, aerospace including satellite, spaceflight, and unmanned aerial vehicle (UAV) components, biotech and pharmaceutical lab automation, semiconductor wafer handling, and transportation customers.
Management believes these acquisitions strengthen PMGC’s position in sectors where reliability, technical certification, and high switching costs support long-term customer retention and value creation.
Near-Term Priorities
Looking ahead, PMGC intends to pursue both organic growth and selective acquisitions that expand operational scale and deepen its presence in markets with favorable long-term fundamentals. The Company’s near-term priorities include:
• Organic growth, integration, and margin improvement across its precision manufacturing and specialty packaging subsidiaries;
• Selective, accretive acquisitions in aerospace, defense, and adjacent vertical markets that expand operational scale;
• Continued advancement of Northstrive Biosciences Inc.’s multi-asset biopharmaceutical pipeline focused on muscle preservation and obesity in the context of GLP-1 receptor agonist weight loss therapies, including EL-22’s FDA-supported path toward a Phase 2 IND submission; and
• Evaluation of M&A capital structures and accretive financing alternatives designed to support the Company’s next phase of growth.
PMGC remains focused on allocating capital into assets capable of generating sustainable cash flow, long-term compounding, and shareholder value creation.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact: IR@pmgcholdings.com
Link article
$ELAB 🗞️
INV4
2月前
Good morning boston127 😊 Personally, I 'always' find it a bit tricky to buy (or buy back in) right after a big run. In the articles below you will find more information about ELAB.
==================
PMGC Holdings dips 50% after massive rally: What's going on with ELAB stock
April 2, 2026
PMGC Holdings Inc. ELAB shares surged 133% during regular trading to $14.00 before dropping 50% in after-hours trading to $7.00. The volatility comes after the company announced a $4.55 million common stock issuance to Streeterville Capital, LLC under its $20 million equity line of credit (ELOC). Investors appear to be reacting to the mechanics of the ELOC and the potential dilution from future share issuances.
Details On Deals, Agreements
The stock movement is linked to PMGC Holdings Inc.‘s prospectus supplement filed on April 1, 2026, offering $4,551,804 in common stock directly to Streeterville Capital, LLC under an existing $20,000,000 equity line of credit facility signed in September 2025. This marks the fourth draw under the agreement, following prior draws in September 2025, and January and February 2026. Shares will be issued at 88% of the lowest daily volume-weighted average price over the preceding ten trading days. Univest Securities, LLC acts as placement agent, earning 8% of gross proceeds.
Executive Quotes
PMGC Holdings emphasizes its acquisition-focused strategy: "At PMGC, we're buying, holding legacies. Our focus is on operational continuity, keeping founders, families, and employees engaged while supporting growth with our capital and platform."
Company Overview
PMGC Holdings Inc. is a diversified holding company focused on acquiring cash-flowing businesses in the manufacturing sector. The company follows a long-term "permanent capital" approach, aiming to preserve and grow acquired businesses while maintaining operational continuity. Its model emphasizes keeping founders, families, and existing management teams involved, supported by PMGC's financial resources and platform.
Trading Metrics And Technical Analysis
With a market capitalization of $16.23 million, PMGC Holdings has a 52-week high of $466.20 and a 52-week low of $1.62.
Over the past 12 months, the small-cap stock of the manufacturing-focused holding company has declined 96.34%.
Price Action: According to Benzinga Pro data, ELAB closed the regular session at $14.00, up 133.72%.
The stock is trading significantly below its 52-week high.
Benzinga’s Edge Stock Rankings show that ELAB is exhibiting a negative price trend across all time frames.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Link article
==================
PMGC Holdings Signs Defense Agreement, Sees Asset Boost
April 1, 2026
PMGC Holdings Inc.’s stock rallies 16.36% driven by regulatory approvals and strategic partnerships boosting investor confidence.
Quick Financial Overview
PMGC Holdings, recognized by the ticker symbol ELAB, presents a robust picture with a reported 43% surge in assets, peaking at approximately $12.9M. But what drives this growth? It’s primarily their strategic acquisitions in precision manufacturing and IT hardware packaging. These moves allow PMGC to ride the trends in data centers and defense, sectors that are gaining importance amidst reshoring dynamics.
Diving a bit deeper, ELAB’s NorthStrive Biosciences arm shows promise, especially with its therapeutic muscle-preservation products intended to partner with popular weight-loss drugs. An FDA-supported IND path to move into Phase 2 trials for their creation EL-22, along with exciting preclinical work on EL-32, points to significant progress.
Financially, the firm seems like it’s walking on a tightrope. Despite having revenue numbers around $590,084, certain ratios betray a struggle. For instance, a gross margin sits at 27.3%, giving a glimmer of hope, albeit overshadowed by an overwhelming negative EBIT margin of -1483.5%.
Market Reactions
There’s a wave of optimism as PMGC’s subsidiary AGA Precision Systems inks a five-year renewable deal. This agreement with Turbo-Jet Products involves critical components for aerospace and defense applications. It’s a noteworthy development that follows their recent AS9100 certification and ITAR compliance, enabling deeper penetration in regulated sectors.
Such contracts often pivot corporations into more advantageous bargaining positions, increasing volume while possibly decorrelating risk due to contract security. PMGC’s involvement in a joint effort for these components aligns its business goals with the broader defense initiatives, reflecting positively on future stock sentiment.
Adding to the narrative is the intriguing leap into biotechnology. NorthStrive’s venture with biotech heavyweight MOA Life Plus enhances its offerings with EL-22 and EL-32, extending timelines while meeting R&D and regulatory checkpoints. These moves are not just strategic but also push PMGC closer to key pharmaceutical market players, aligning its bio solutions with the demand surge for GLP-1 based weight management drugs.
Link article
==================
Why ELAB Stock Is Crashing Over 50% Overnight After 8x Surge This Week
April 2, 2026
ELAB Dilution Concerns
PMGC Holdings is raising another $4.55 million by issuing discounted stock to Streeterville Capital under an ongoing equity line, while registering those shares for resale, according to an exchange filing late Wednesday.
Link article
$ELAB 🗞️
INV4
2月前
AGA Precision Systems, wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), Signs Long-Term Agreement to Supply Mission-Critical Aerospace and Defense Components to Turbo-Jet Products
March 31, 2026
AGA Precision Systems LLC (“AGA”), a precision aerospace manufacturing company and wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today announced the execution of a Long-Term agreement (“LTA”) with Turbo-Jet Products Co., Inc. (“Turbo-Jet Products”), a California-based aerospace and defense supplier.
Under the terms of the LTA, AGA will supply mission-critical aerospace and defense components in support of Turbo-Jet Products’ commercial and defense programs. The LTA provides an agreement framework that governs all future purchase orders issued during the LTA’s term.
The LTA includes an initial five-year term, with provisions for annual renewals, supporting a long-term strategic supply relationship between the parties.
Strategic Importance
The company believes this LTA strengthens AGA’s position within the aerospace and defense supply chain and enables AGA to support programs that may include U.S. government and defense-related contracts, in compliance with applicable Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) requirements.
The LTA follows AGA’s achievement of AS9100 certification, a globally recognized quality standard for aerospace manufacturing, and its International Traffic in Arms Regulations (“ITAR”) compliance, reinforcing the company’s ability to support regulated defense programs and deliver mission-critical components with the highest levels of quality, traceability, and regulatory adherence.
About AGA Precision Systems LLC
AGA Precision Systems LLC is a California-based specialized computer numerical control machine shop focused on high-tolerance milling, turning, mold manufacturing, and machining of complex metals. The company serves customers across the aerospace, defense, space, and industrial sectors, delivering precision components to demanding technical specifications.
AGA is AS9100 certified and ITAR compliant, meeting globally recognized quality management standards for aerospace manufacturing and adhering to strict U.S. regulatory requirements for defense-related work.
About Turbo-Jet Products Co., Inc.
Since 1948, Tur-Bo Jet Products has been providing custom innovative design, manufacturing, and solutions for the aerospace, military, transportation, and medical industries. Turbo-Jet Products is an AS9100 Rev. D / ISO 9001:2015 certified designer and manufacturer of custom electromagnetic, electromechanical, mechanical, fluid, and pneumatic controls.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Contact:
Email: IR@pmgcholdings.com
Link article
$ELAB 🗞️
iHub News
2月前
PMGC Holdings reports 43% increase in assets, completes three acquisitionsMarch 30, 2026 10:24 AM
IH Market News
PMGC Holdings Inc. (NASDAQ:ELAB) filed its fiscal 2025 annual report on Monday, reporting that total assets grew 43% year-over-year to about $12.87 million, up from $8.99 million in 2024, according to a company press release. The company currently has a market capitalization of roughly $0.9 million and a Price-to-Book ratio of 0.28, placing it among the lowest in its sector.During 2025, the company completed three acquisitions across the precision manufacturing and industrial packaging industries. Pacific Sun Packaging, acquired on July 7, specializes in packaging solutions for semiconductor and data infrastructure components and serves more than 300 customers throughout North America. AGA Precision Systems, acquired on July 18, operates as a certified precision manufacturer supplying aerospace and defense clients, holding both ITAR registration and AS9100 certification. On October 26, the company finalized a third transaction through AGA with the purchase of assets from Indarg Engineering, aimed at expanding machining capacity.Shareholders’ equity increased to approximately $7.84 million, compared with $6.66 million the previous year.PMGC’s biopharmaceutical subsidiary, Northstrive Biosciences, received preliminary feedback from the U.S. Food and Drug Administration indicating that existing nonclinical and Phase 1 data for EL-22 — an oral probiotic designed to help maintain muscle mass in patients using GLP-1 weight-loss therapies — appears sufficient to support advancement into a Phase 2 clinical trial in the United States. In March 2026, Northstrive also initiated a preclinical study of EL-32 to evaluate muscle preservation in a diet-induced obesity mouse model.In February 2026, Northstrive Biosciences signed a royalty-bearing licensing agreement with Modulant Biosciences LLC covering worldwide development of EL-22- and EL-32-derived products for animal health applications. PMGC retains exclusive rights to human therapeutic uses of the technologies.Northstrive’s artificial intelligence development program, conducted in partnership with Yuva Biosciences, progressed to the experimental validation stage in December 2025. The program is focused on identifying small-molecule candidates aimed at improving mitochondrial health and preserving muscle mass. Phase III results are expected in the second quarter of 2026.Separately, PMGC Holdings recently announced that NorthStrive Biosciences has launched a preclinical study of EL-32, an engineered probiotic candidate designed to preserve lean muscle while promoting fat loss. The study will test EL-32 both as a standalone therapy and in combination with GLP-1 weight-loss treatments in a diet-induced obesity mouse model. The company also disclosed the filing of ten new U.S. patent applications related to its proprietary EL-22 and EL-32 technologies, expanding potential applications in animal health and agricultural markets. Additionally, PMGC reported completing a 1-for-6 reverse stock split of its common shares, which became effective on March 10, 2026.On the corporate governance front, PMGC amended consulting agreements with its Chief Executive Officer and Chairman, setting their annual consulting compensation at $300,000 starting January 1, 2026. Meanwhile, subsidiary Northstrive Biosciences executed a third amendment to its licensing agreement with MOA Life Plus Co., Ltd., revising milestone timelines related to preclinical development stages. These developments reflect PMGC’s ongoing strategic adjustments across both its corporate structure and research initiatives.PMGC Holdings stock price
Original: PMGC Holdings reports 43% increase in assets, completes three acquisitions
INV4
2月前
PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024
March 30, 2026
MWN-AI** Summary
PMGC Holdings Inc. (NASDAQ: ELAB) reported substantial growth in its 2025 Annual Results, revealing a 43% increase in total assets, which rose from $8.99 million in 2024 to approximately $12.87 million by the end of 2025. Shareholders' equity also saw a rise, climbing from $6.66 million to about $7.84 million during the same period. This remarkable growth reflects the company’s strategic focus on acquiring operational businesses in precision manufacturing and IT packaging, sectors known for their robust demand and high technical barriers.
In 2025, PMGC completed three key acquisitions: Pacific Sun Packaging, which specializes in protective packaging for IT hardware; AGA Precision Systems, a certified manufacturer in the aerospace and defense sectors; and Indarg Engineering, aimed at enhancing AGA's capacity. These acquisitions solidify PMGC’s footprint in industries that require reliability and technical expertise, ensuring lasting customer relationships.
Additionally, PMGC's biopharmaceutical subsidiary, Northstrive Biosciences, made strides with its dual Myostatin assets, targeting muscle preservation alongside GLP-1 treatments. Their lead asset, EL-22, is progressing towards Phase 2 clinical trials, showing promise in preserving muscle mass for patients undergoing weight loss therapies.
Looking forward to 2026, PMGC plans to enact both organic growth strategies and continued selective acquisitions to strengthen its market position further. The company's commitment to enhancing its asset base and exploring diverse sectors indicates a strategic approach to maximizing long-term shareholder value. For further details, stakeholders can access the full Annual Report filed with the SEC.
MWN-AI** Analysis
PMGC Holdings Inc. (NASDAQ: ELAB) has reported promising results for its fiscal year ending December 31, 2025, showcasing a strategic approach to capital allocation and asset growth. With total assets surging 43% to approximately $12.87 million and a notable increase in shareholders' equity, the company appears to be solidifying its foothold in high-demand sectors such as aerospace, defense, and IT packaging.
The acquisitions of Pacific Sun Packaging and AGA Precision Systems position PMGC in industries characterized by high technical barriers, critical applications, and durable demand, which are expected to bolster cash flow in the coming years. These sectors benefit from national policy shifts towards increased domestic production, particularly in defense, making the company's investments timely and strategically sound.
Moreover, PMGC’s biopharmaceutical subsidiary, Northstrive Biosciences, emphasizes muscle preservation approaches positioned to capture a share of the burgeoning GLP-1 therapeutic market. This diversification into biopharmaceuticals, complemented by ongoing AI-driven drug discovery efforts, could potentially enhance long-term shareholder value.
Investors should consider the company's focus on sectors with significant growth drivers, supported by federal initiatives and technological advancements. The rigorous requalification processes in the defense and aerospace sectors further ensure high customer retention, potentially stabilizing revenues.
Looking ahead to 2026, PMGC’s strategy involves both organic growth initiatives and additional acquisitions to expand operational scale within its chosen verticals. The combination of disciplined capital allocation and strategic acquisitions reflects a commitment to creating sustainable growth.
Overall, PMGC's performance illustrates it as an attractive option for investors seeking exposure in resilient sectors with considerable upside potential. As always, investors should weigh these insights against inherent risks and conduct thorough due diligence before making investment decisions.
================
March 30, 2026
Source: GlobeNewswire
• Deploys Capital into Cash-Flowing Manufacturing Businesses in Aerospace, Defense and IT Packaging
• Advances Dual Myostatin Assets Targeting Muscle Preservation in Potential Combination with GLP-1 Treatments
NEWPORT BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“the Company,” “PMGC,” “we,” or “our”) today filed its Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2025 (“FYE 2025”), with the U.S. Securities and Exchange Commission (“SEC”).
The Annual Report is available on the SEC’s website at www.sec.gov under the Company’s filings and on the Company’s investor relations website.
A Year of Capital Allocation and Asset Growth
Fiscal 2025 marked a year of disciplined capital deployment and balance sheet expansion.
• Total assets increased 43%, from approximately $8.99 million in the fiscal year ending December 31, 2024 (“FYE 2024”) to approximately $12.87 million in FYE 2025.
• Shareholders’ equity increased from approximately $6.66 million in FYE 2024 to approximately $7.84 million in FYE 2025.
This growth was driven primarily by acquisitions of operating businesses in sectors characterized by durable demand, technical specialization, and supply chain importance.
PMGC continues to focus on allocating capital into assets capable of generating sustainable cash flow and long-term compounding.
Acquiring a Portfolio of Operating Businesses
In FYE 2025, PMGC completed 3 acquisitions across precision manufacturing and industrial packaging. These businesses share core attributes:
• High technical barriers to entry;
• Mission-critical applications;
• Established blue chip customer bases; and
• Exposure to U.S. industrial and defense supply chain demand.
Acquisitions Completed:
Pacific Sun Packaging, Inc. — Acquired on July 7, 2025
Pacific Sun Packaging, Inc. (“Pacific Sun Packaging”) is a provider of specialized packaging solutions for semiconductor and data infrastructure components. Headquartered in San Clemente, California, Pacific Sun Packaging designs custom-engineered protective packaging for CPUs, memory modules, SSDs, fiber-optic transceivers, and other sensitive information technology (“IT”) hardware, serving over 300 commercial customers across North America’s semiconductor, data center and IT supply chains.
AGA Precision Systems LLC — Acquired on July 18, 2025
AGA Precision Systems LLC (“AGA”) is a certified precision manufacturer serving aerospace and defense customers, including International Traffic in Arms Regulations (“ITAR”)-regulated work. AGA specializes in high-tolerance computer numerical control milling, turning, and machining of complex metals such as titanium and Inconel, and holds both ITAR registration and AS9100 certification.
Indarg Engineering, Inc. (Asset Acquisition) — Acquired on October 26, 2025
Indarg Engineering, Inc. was a bolt-on acquisition completed through PMGC’s subsidiary, AGA. The acquisition expanded AGA’s machining capacity and operational scale to support growing demand from aerospace and industrial customers.
Management believes the acquisitions listed above strengthen PMGC’s position in sectors where reliability and high switching costs support long-term customer retention and value creation.
Positioned in Durable, High-Value Industries
The acquisitions completed in FYE 2025 place PMGC squarely within two industrial verticals: precision manufacturing and specialty IT hardware packaging, where the Company believes structural demand drivers support continued growth into 2026 and beyond.
Precision Manufacturing
PMGC believes U.S. defense spending, aerospace production backlogs, and federal reshoring initiatives continue to drive demand for certified, domestic machine shops. Qualified domestic manufacturers holding both ITAR registration and AS9100D certification represent a narrow segment of the broader U.S. machining industry. As prime defense contractors and Tier 1 aerospace customers increasingly prioritize onshoring and supply chain security, demand for certified, U.S.-based precision shops continues to grow. The Company believes that once qualified as a supplier on a program, customer retention is reinforced by the rigorous requalification processes and first article inspection requirements associated with changing manufacturers.
Specialty Packaging
The continued buildout of data center infrastructure, driven by cloud computing, artificial intelligence, and enterprise IT refresh cycles, is generating increased demand for precision component-level packaging that protects high-value semiconductors, memory, and networking hardware. PMGC believes Pacific Sun Packaging’s established relationships with original equipment manufacturers, distributors, and data center operators position it to benefit from this investment cycle.
Looking ahead to 2026, PMGC intends to pursue both organic and selective acquisitions that expand operational scale and deepen its presence in markets with favorable long-term fundamentals.
Northstrive Biosciences: Advancing a Multi-Asset Biopharma Pipeline
Northstrive Biosciences Inc. (“Northstrive Biosciences”), PMGC’s biopharmaceutical subsidiary, advanced multiple initiatives in the aggregate during FYE 2025 and early 2026, spanning clinical-stage development, preclinical research, AI-driven drug discovery, and commercial licensing. All programs focus on muscle preservation in the context of GLP-1 receptor agonist weight loss therapies, a rapidly growing therapeutic class.
EL-22 — FDA Supports Path to Phase 2 IND Submission
EL-22, Northstrive Bioscience’s lead asset, is a first-in-class engineered oral probiotic designed to preserve muscle mass in patients on GLP-1 weight loss treatments. Following a completed Phase 1 clinical trial in South Korea demonstrating favorable safety and tolerability, preliminary U.S. Food and Drug Administration (“FDA”) feedback indicated that Northstrive Biosciences’s nonclinical and Phase 1 data appear adequate to support initiation of a Phase 2 clinical trial in the USA. Northstrive Biosciences believes the FDA has provided a clear path forward for filing an Investigational New Drug application to conduct a Phase 2 trial evaluating EL-22 in combination with GLP-1 receptor agonists for obesity. Northstrive Biosciences is evaluating licensing, strategic partnerships, and direct development pathways for clinical advancement, subject to available financing.
EL-32 — Preclinical Study Underway
In March 2026, Northstrive Biosciences initiated a preclinical study for EL-32, a dual-action engineered probiotic candidate expressing both myostatin and activin-A antigens. This study uses a diet-induced obesity mouse model to evaluate muscle preservation and fat loss both as a standalone therapy and in combination with semaglutide. Dosing and observation are currently underway.
Modulant Biosciences — Animal Health License Agreement Executed
In February 2026, Northstrive Biosciences executed an exclusive, royalty-bearing license agreement with Modulant Biosciences LLC for the worldwide development and commercialization of EL-22 and EL-32 derived products in non-human animal health applications, including feed additives. Northstrive Biosciences retains all human therapeutic rights. Through this agreement, the parties aim to convert Northstrive Bioscience’s proprietary technology into a potential revenue-generating asset within the global animal health market.
Yuva Biosciences — AI Drug Discovery Advances to Experimental Validation
Northstrive’s AI Development Program with Yuva Biosciences, Inc. (“YuvaBio”) progressed to Phase III in December 2025, moving from computational screening to experimental validation of small-molecule candidates identified by YuvaBio’s MitoNova™ platform. This program targets compounds that may support mitochondrial health and muscle preservation in GLP-1-treated patients. YuvaBio has since deployed improved sixth-generation classifier models and Phase III results are currently expected in Q2 2026.
Together, the above Northstrive Biosciences programs position it with a differentiated oral approach to muscle preservation, an area where existing therapies remain limited to injectable delivery.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact: IR@pmgcholdings.com
Link article
$ELAB 🗞️
INV4
2月前
NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments
March 27, 2026
NorthStrive Biosciences (NASDAQ: ELAB) announced a third amendment to its License Agreement with MOA Life Plus (KOSDAQ: 142760) covering dual myostatin assets EL-32 and EL-22.
The Amendment updates the timing and key development milestones for human clinical programs, aligning schedules with both parties' R&D and regulatory expectations and reinforcing disciplined development planning for the human health portfolio.
NEWPORT BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc.’s (NASDAQ: ELAB) (“PMGC,” “we,” or “our”) wholly owned subsidiary, NorthStrive Biosciences Inc. (“Northstrive Biosciences”), announced today a third amendment (“Amendment”) to its existing License Agreement with MOA Life Plus Co., Ltd., [KOSDAQ: 142760] a Korean biotechnology company (“MOA,” and such existing agreement, as amended, “License Agreement”) Northstrive Biosciences holds for EL-32 and EL-22.
The Amendment updates the timing and key development milestones for EL-32 and EL-22 human clinical development programs, aligning the schedule with the parties’ research and development and regulatory expectations.
Northstrive Biosciences believes the Amendment reinforces the company’s commitment to disciplined development planning and the continued progression of its human health portfolio.
About MOA Life Plus Co. Ltd. [KOSDAQ: 142760]
MOA Life Plus Co. Ltd.is a Korean biotechnology company focused on the research, development, and commercialization of innovative therapeutic and wellness technologies. MOA partners globally to advance scientific innovation across human and animal health applications.
About NorthStrive Biosciences Inc.
NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. NorthStrive’s lead asset, EL-22, leverages an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
IR@pmgcholdings.com
Link article
=================
SVM Machining, Inc. Secures ITAR Registration, Enabling Entry into U.S. Defense Manufacturing Contracts
March 24, 2026
NEWPORT BEACH, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: PMGC) (“PMGC” or the “Company”), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, is pleased to announce that its wholly owned subsidiary, SVM Machining, Inc. dba Silicon Valley Manufacturing (“SVM”), has completed International Traffic in Arms Regulations (“ITAR”) registration and is in compliance with ITAR. The ITAR is administered by the U.S. State Department’s Directorate of Defense Trade Controls, which controls the export and import of defense articles and services.
The Company believes this completed ITAR registration will further enable SVM to pursue defense and aerospace programs that require compliance with U.S. export-control standards. Also, the Company believes this milestone enhances SVM’s eligibility as a qualified supplier to Tier 1 defense contractors and aerospace original equipment manufacturers. The registration supports the Company’s broader strategy to expand into high-value, defense-related manufacturing.
About SVM Machining, Inc.SVM Machining, Inc. dba Silicon Valley Manufacturing is a California-based ISO 9001:2015 Certified precision CNC machining and manufacturing services company that produces high-quality, engineered components for a diverse set of mission-critical industries, including medical technology, aerospace, semiconductor, biotech & pharmaceutical, and transportation. Known for its technical expertise, quality systems, and ability to deliver complex parts with precision tolerances, SVM supports original equipment manufacturers and advanced technology customers with reliable and responsive production capacity. For more information, please visit https://svmfg.com.
About PMGC Holdings Inc.PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:IR@pmgcholdings.com
$ELAB 🗞️
INV4
4月前
NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health
Feb 11, 2026
NorthStrive Biosciences Inc. (“NorthStrive”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced that it has executed a definitive, exclusive license agreement (“License Agreement”) with Modulant Biosciences LLC (“Modulant”), following the previously announced binding term sheet dated May 12, 2025.
The License Agreement covers NorthStrive’s EL-22 and EL-32 assets and, pursuant to its terms, grants Modulant an exclusive, royalty-bearing, sublicensable license to develop, manufacture, and commercialize products derived from these technologies solely for non-human animal health applications, including use as a feed additive. This license (“License”) applies on a worldwide basis, excluding the Republic of Korea. Modulant agreed to pay value to NorthStrive in exchange for the License granted under the License Agreement.
EL-22 and EL-32 are based on proprietary intellectual property targeting myostatin and activin-A pathways, which are key biological regulators of muscle development, strength, and metabolic efficiency. These pathways are increasingly viewed as important targets across a range of animal health and nutrition applications, including livestock productivity, feed efficiency, and companion animal muscle health and aging.
The License Agreement encompasses issued patents, pending patent applications, and associated proprietary know-how underlying the EL-22 and EL-32 programs. Under the terms of the License Agreement, Modulant is responsible for all development, manufacturing, regulatory, and commercialization activities for licensed products within the animal health field, using commercially reasonable efforts. The License Agreement expressly excludes any human pharmaceutical or clinical applications.
The License Agreement also provides for:
• Certain development, commercialization, and reporting obligations;
• Modulant’s ability to grant sublicenses to the License, subject to the terms of the License Agreement;
• NorthStrive and Modulant’s shared ownership of improvements and newly created intellectual property related to licensed products; and
• Certain ongoing regulatory compliance and abidance with quality standards customary in the animal health and feed additive industries.
The collaboration represented by this License Agreement between NorthStrive and Modulant is intended to advance EL-22– and EL-32-derived products toward commercialization in the global animal health market, which continues to grow alongside rising demand for improved animal performance, wellness, and longevity.
The execution of the License Agreement represents a key milestone for NorthStrive, converting the previously announced term sheet into a fully executed definitive agreement that enables focused development and commercialization activities for EL-22 and EL-32 within the animal health sector.
While the definitive licensing agreement provides a framework for the development and commercialization of EL-22 and EL-32 for animal health applications, there can be no assurance that Modulant will be successful in developing, obtaining any required regulatory approvals for, or commercializing products derived from these technologies, or that any such products will achieve market acceptance.
About NorthStrive Biosciences Inc.
NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. NorthStrive’s lead asset, EL-22, leverages an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
About Modulant Biosciences LLC
Modulant Biosciences is a biotechnology company specializing in veterinary medicine innovation. Led by Dr. Tom Campi, Modulant is focused on developing novel drugs and biologics for livestock, companion, and aquatic animals. Currently, Modulant’s synergistic pipeline includes first in class antivirals for livestock and companion animals and a “One Drug for All Cancers” platform.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
IR@pmgcholdings.com
Link
$ELAB 🗞️
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
zeusgodmd
4週前
Zardiw
2月前
RiskAndReason
2月前
glenn1919
4月前
KeepOn
4月前
georgie18
5月前
firebag1
9月前
TrendTrade2016
9月前
メールアドレスで登録
